3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
29
Breast Neoplasms
17
Neoplasms
14
Neoplasm Metastasis
10
Ovarian Neoplasms
9
Carcinoma, Renal Cell
8
Melanoma
7
Leukemia, Lymphocytic, Chronic, B-Cell
7
Colorectal Neoplasms
7
Urinary Bladder Neoplasms
6
Small Cell Lung Carcinoma
6
Recurrence
6
Multiple Myeloma
6
Lymphoma, Non-Hodgkin
6
Thyroid Neoplasms
5
Thyroid Cancer, Papillary
5
Prostatic Neoplasms
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Pancreatic Neoplasms
5
Lung Neoplasms
5
Hematologic Neoplasms
5
Head and Neck Neoplasms
5
Endometrial Neoplasms
5
Colonic Neoplasms
5
Lymphoma
4
Leukemia, Myeloid, Acute
4
Urothelial Cancer
3
Stomach Neoplasms
3
Sarcoma
3
Salivary Gland Neoplasms
3
Interventions
venetoclax
1
obinutuzumab
1
acalabrutinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Has announcements
×
Leukemia, B-Cell
×
Clear all
NCT03836261
2024-12-27
AMPLIFY
Acerta Pharma BV
Phase 3
Active not recruiting
984 enrolled
1 FDA